Featured Publications
Urine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis
Moledina DG, Wilson FP, Kukova L, Obeid W, Luciano R, Kuperman M, Moeckel GW, Kashgarian M, Perazella MA, Cantley LG, Parikh CR. Urine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis. Nephrology Dialysis Transplantation 2020, 36: 1851-1858. PMID: 33125471, PMCID: PMC8476079, DOI: 10.1093/ndt/gfaa169.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisTumor necrosis factorCorticosteroid useIL-9Interstitial nephritisNecrosis factorAcute kidney injuryIL-9 levelsGlomerular filtration rateSubset of patientsCohort of participantsImmunosuppressive therapyTubulointerstitial infiltratesKidney injuryMedian eGFRKidney functionUrine biomarkersInterstitial fibrosisFiltration rateHistological featuresClinical trialsInterleukin-9PatientsEGFRComplete data
2023
Urinary Biomarkers and Kidney Injury in VA NEPHRON-D: Phenotyping Acute Kidney Injury in Clinical Trials
Kiernan E, Hu D, Philbrook H, Ix J, Bonventre J, Coca S, Moledina D, Fried L, Shlipak M, Parikh C. Urinary Biomarkers and Kidney Injury in VA NEPHRON-D: Phenotyping Acute Kidney Injury in Clinical Trials. American Journal Of Kidney Diseases 2023, 83: 151-161. PMID: 37726051, PMCID: PMC10841767, DOI: 10.1053/j.ajkd.2023.07.012.Peer-Reviewed Original ResearchAcute kidney injuryKidney injuryClinical trialsSerum creatinineUrinary biomarkersAKI eventsVA NEPHRONCombination armUrine biomarkersDiabetic chronic kidney disease patientsChronic Kidney Disease trialChronic kidney disease patientsAldosterone system blockadeCombination therapy armKidney Disease TrialRAAS inhibitor therapySafety end pointCombination therapy groupKidney disease patientsBiomarkers of injuryAKI incidenceKidney outcomesMonotherapy armRAAS blockadeRAASi therapy
2016
Application of new acute kidney injury biomarkers in human randomized controlled trials
Parikh CR, Moledina DG, Coca SG, Thiessen-Philbrook HR, Garg AX. Application of new acute kidney injury biomarkers in human randomized controlled trials. Kidney International 2016, 89: 1372-1379. PMID: 27165835, PMCID: PMC4869991, DOI: 10.1016/j.kint.2016.02.027.Peer-Reviewed Original ResearchConceptsAcute kidney injuryAKI biomarkersKidney injuryClinical trialsNew biomarkersEarly acute kidney injuryObserved relative risk reductionPostoperative acute kidney injuryAcute kidney injury biomarkersHypothetical trialKidney injury progressionMulti-country trialAcute tubular necrosisCardiopulmonary bypass timeClinical risk factorsKidney injury biomarkersProportion of patientsProspective cohort studyKidney injury markersRelative risk reductionAKI progressionAKI trialsBypass timeCohort studyInjury markers